{ "disease": "anal-cancer", "label": "Anal cancer", "url": "https://usebiotransfer.org/disease/anal-cancer/", "built": "2026-09-12", "facts_hash": { "answers": "43ddd8ea7c0b", "targets": "085d18fecb5c" }, "sources": { "targets": "Open Targets Platform GraphQL API v4", "trials": "ClinicalTrials.gov API v2" }, "retrieved": { "targets": "2026-09-12", "trials": "2026-09-12" }, "query": { "endpoint": "https://clinicaltrials.gov/api/v2/studies", "shape": "query.cond=&query.intr=&pageSize=200", "active_statuses": [ "ACTIVE_NOT_RECRUITING", "ENROLLING_BY_INVITATION", "NOT_YET_RECRUITING", "RECRUITING" ], "dedup": "by NCT id across synonyms", "study_types": "interventional counted in headline; observational reported separately", "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search" }, "targets": [ { "symbol": "CD274", "ensembl": "ENSG00000120217", "n_drug_entries": 13, "n_distinct_drugs": 13, "drugs": { "ADEBRELIMAB": "PHASE_3", "ATEZOLIZUMAB": "APPROVAL", "AVELUMAB": "APPROVAL", "BINTRAFUSP ALFA": "PHASE_3", "COSIBELIMAB": "APPROVAL", "DANBURSTOTUG": "PHASE_2", "DURVALUMAB": "APPROVAL", "ENVAFOLIMAB": "PHASE_3", "ERFONRILIMAB": "PHASE_3", "INCB-086550": "PHASE_2", "PACMILIMAB": "PHASE_2", "SOCAZOLIMAB": "PHASE_3", "SUGEMALIMAB": "APPROVAL" }, "approved": [ "ATEZOLIZUMAB", "AVELUMAB", "COSIBELIMAB", "DURVALUMAB", "SUGEMALIMAB" ], "n_approved": 5, "approved_for": { "ATEZOLIZUMAB": [ "urothelial carcinoma", "non-small cell lung carcinoma", "breast cancer", "small cell lung carcinoma", "breast neoplasm", "transitional cell carcinoma" ], "AVELUMAB": [ "Merkel cell skin cancer", "urothelial carcinoma", "neuroendocrine neoplasm" ], "COSIBELIMAB": [ "head and neck squamous cell carcinoma" ], "DURVALUMAB": [ "non-small cell lung carcinoma", "small cell lung carcinoma", "urothelial carcinoma", "hepatocellular carcinoma" ], "SUGEMALIMAB": [ "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "PDCD1", "ensembl": "ENSG00000188389", "n_drug_entries": 26, "n_distinct_drugs": 26, "drugs": { "APL-501": "PHASE_2", "BALSTILIMAB": "PHASE_3", "BUDIGALIMAB": "PHASE_2_3", "CADONILIMAB": "PHASE_3", "CAMRELIZUMAB": "PHASE_3", "CEMIPLIMAB": "APPROVAL", "CETRELIMAB": "PHASE_3", "CS-1003": "PHASE_3", "DOSTARLIMAB": "APPROVAL", "FINOTONLIMAB": "PHASE_3", "LOMVASTOMIG": "PHASE_2", "NIVOLUMAB": "APPROVAL", "PEMBROLIZUMAB": "APPROVAL", "PENPULIMAB": "PHASE_3", "PIDILIZUMAB": "PHASE_2", "PIMIVALIMAB": "PHASE_2", "PUCOTENLIMAB": "PHASE_3", "RETIFANLIMAB": "APPROVAL", "SASANLIMAB": "PHASE_3", "SERPLULIMAB": "APPROVAL", "SINTILIMAB": "APPROVAL", "SPARTALIZUMAB": "PHASE_3", "TEBOTELIMAB": "PHASE_2_3", "TISLELIZUMAB": "APPROVAL", "TORIPALIMAB": "APPROVAL", "ZIMBERELIMAB": "PHASE_3" }, "approved": [ "CEMIPLIMAB", "DOSTARLIMAB", "NIVOLUMAB", "PEMBROLIZUMAB", "RETIFANLIMAB", "SERPLULIMAB", "SINTILIMAB", "TISLELIZUMAB", "TORIPALIMAB" ], "n_approved": 9, "approved_for": { "CEMIPLIMAB": [ "squamous cell carcinoma", "basal cell carcinoma", "cutaneous squamous cell carcinoma", "cervical cancer" ], "DOSTARLIMAB": [ "endometrial cancer", "endometrial neoplasm" ], "NIVOLUMAB": [ "head and neck cancer", "pleural mesothelioma", "gastric cancer", "melanoma", "non-small cell lung carcinoma", "renal cell carcinoma", "transitional cell carcinoma", "colorectal neoplasm", "Hodgkins lymphoma", "mesothelioma", "head and neck squamous cell carcinoma", "classic Hodgkin lymphoma", "metastatic melanoma" ], "PEMBROLIZUMAB": [ "melanoma", "metastatic melanoma", "endometrium neoplasm", "head and neck squamous cell carcinoma", "transitional cell carcinoma", "renal cell carcinoma", "Hodgkins lymphoma", "non-small cell lung carcinoma" ], "RETIFANLIMAB": [ "neuroendocrine carcinoma", "Merkel cell skin cancer", "squamous cell carcinoma" ], "SERPLULIMAB": [ "esophageal squamous cell carcinoma", "non-small cell lung carcinoma", "small cell lung carcinoma" ], "SINTILIMAB": [ "Hodgkins lymphoma" ], "TISLELIZUMAB": [ "esophageal cancer", "Hodgkins lymphoma", "non-small cell lung carcinoma", "adenocarcinoma", "esophageal squamous cell carcinoma", "gastric neoplasm" ], "TORIPALIMAB": [ "melanoma", "nasopharyngeal carcinoma", "urothelial carcinoma", "esophageal squamous cell carcinoma", "Niemann-Pick disease type B" ] }, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "PIK3CA", "ensembl": "ENSG00000121879", "n_drug_entries": 32, "n_distinct_drugs": 31, "drugs": { "ALPELISIB": "APPROVAL", "APITOLISIB": "PHASE_2", "AZD-6482": "UNKNOWN", "BAY-1082439": "PHASE_1", "BGT-226": "PHASE_1_2", "BUPARLISIB": "PHASE_3", "COPANLISIB": "APPROVAL", "DACTOLISIB": "PHASE_3", "DS-7423": "PHASE_1", "FIMEPINOSTAT": "PHASE_2", "GEDATOLISIB": "PHASE_3", "GSK-1059615": "PHASE_1", "INAVOLISIB": "APPROVAL", "IZORLISIB": "PHASE_1_2", "OMIPALISIB": "PHASE_1", "PANULISIB": "PHASE_1", "PAXALISIB": "PHASE_2_3", "PF-04691502": "PHASE_2", "PICTILISIB": "PHASE_2", "PILARALISIB": "PHASE_2", "PKI-179": "PHASE_1", "RECILISIB": "PHASE_1", "SAMOTOLISIB": "PHASE_2", "SERABELISIB": "PHASE_2", "SF-1126": "PHASE_2", "SONOLISIB": "PHASE_2", "TASELISIB": "PHASE_3", "VOXTALISIB": "PHASE_2", "VS-5584": "PHASE_1", "WX-037": "PHASE_1", "ZSTK-474": "PHASE_1" }, "approved": [ "ALPELISIB", "COPANLISIB", "INAVOLISIB" ], "n_approved": 3, "approved_for": { "ALPELISIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "COPANLISIB": [ "follicular lymphoma", "non-Hodgkin lymphoma", "neoplasm of mature B-cells" ], "INAVOLISIB": [ "breast neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "CDKN2A", "ensembl": "ENSG00000147889", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [] }, { "symbol": "TP53", "ensembl": "ENSG00000141510", "n_drug_entries": 9, "n_distinct_drugs": 8, "drugs": { "ALRIZOMADLIN": "PHASE_2", "CENERSEN": "PHASE_2", "CONTUSUGENE LADENOVEC": "PHASE_3", "EPRENETAPOPT": "PHASE_3", "IDASANUTLIN": "PHASE_3", "NAVTEMADLIN": "PHASE_3", "SIREMADLIN": "PHASE_2", "TEPRASIRAN": "PHASE_3" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Advanced Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "EGFR", "ensembl": "ENSG00000146648", "n_drug_entries": 82, "n_distinct_drugs": 74, "drugs": { "ABIVERTINIB": "PHASE_3", "AC-480": "PHASE_2", "AEE-788": "PHASE_1_2", "AFATINIB": "APPROVAL", "AFATINIB DIMALEATE": "APPROVAL", "ALLITINIB": "PHASE_1", "AMIVANTAMAB": "APPROVAL", "AUMOLERTINIB": "APPROVAL", "AV-412": "PHASE_1", "AZD-3759": "PHASE_2_3", "AZD-4769": "PHASE_1", "BAFISONTAMAB": "PHASE_2", "BMS-690514": "PHASE_2", "BRIGATINIB": "APPROVAL", "CANERTINIB": "PHASE_2", "CEP-32496": "PHASE_1_2", "CETUXIMAB": "APPROVAL", "CETUXIMAB SAROTALOCAN": "APPROVAL", "CLN-081": "PHASE_3", "CUDC-101": "PHASE_1", "DACOMITINIB": "APPROVAL", "DEPATUXIZUMAB": "PHASE_2", "DEPATUXIZUMAB MAFODOTIN": "PHASE_3", "DULIGOTUZUMAB": "PHASE_2", "EPITINIB": "PHASE_1", "ERLOTINIB": "APPROVAL", "FALNIDAMOL": "PHASE_1", "FIRMONERTINIB": "PHASE_3", "FUTUXIMAB": "PHASE_3", "GC1118": "PHASE_2", "GEFITINIB": "APPROVAL", "ICOTINIB": "APPROVAL", "IMGATUZUMAB": "PHASE_2", "JNJ-26483327": "PHASE_1", "KBP5209": "PHASE_1", "LAPATINIB": "APPROVAL", "LAPATINIB DITOSYLATE": "APPROVAL", "LAZERTINIB": "APPROVAL", "LOSATUXIZUMAB VEDOTIN": "PHASE_1", "MAB-425": "UNKNOWN", "MATUZUMAB": "PHASE_2", "MAVELERTINIB": "PHASE_1_2", "MDX-447": "PHASE_1", "MOBOCERTINIB": "APPROVAL", "MODOTUXIMAB": "PHASE_2", "NAQUOTINIB": "PHASE_3", "NAZARTINIB": "PHASE_3", "NECITUMUMAB": "APPROVAL", "NERATINIB": "APPROVAL", "NIMOTUZUMAB": "APPROVAL", "OLMUTINIB": "APPROVAL", "OSIMERTINIB": "APPROVAL", "PANITUMUMAB": "APPROVAL", "PELITINIB": "PHASE_2", "PF-06459988": "PHASE_2", "PIMURUTAMAB": "PHASE_2_3", "PKI-166": "PHASE_2", "POZIOTINIB": "PHASE_3", "PYROTINIB": "PHASE_3", "RINDOPEPIMUT": "PHASE_3", "ROCILETINIB": "APPROVAL", "RUSERONTINIB": "PHASE_3", "S-222611": "PHASE_1", "SAPITINIB": "PHASE_2", "SIMOTINIB": "PHASE_1", "TAK-285": "PHASE_1", "TARLOXOTINIB": "PHASE_2", "TESEVATINIB": "PHASE_3", "THELIATINIB": "PHASE_1", "TOMUZOTUXIMAB": "PHASE_2", "TUXOBERTINIB": "PHASE_1_2", "VANDETANIB": "APPROVAL", "VARLITINIB": "PHASE_2_3", "ZALUTUMUMAB": "PHASE_3" }, "approved": [ "AFATINIB", "AFATINIB DIMALEATE", "AMIVANTAMAB", "AUMOLERTINIB", "BRIGATINIB", "CETUXIMAB", "CETUXIMAB SAROTALOCAN", "DACOMITINIB", "ERLOTINIB", "GEFITINIB", "ICOTINIB", "LAPATINIB", "LAPATINIB DITOSYLATE", "LAZERTINIB", "MOBOCERTINIB", "NECITUMUMAB", "NERATINIB", "NIMOTUZUMAB", "OLMUTINIB", "OSIMERTINIB", "PANITUMUMAB", "ROCILETINIB", "VANDETANIB" ], "n_approved": 23, "approved_for": { "AFATINIB": [ "non-small cell lung carcinoma" ], "AFATINIB DIMALEATE": [ "non-small cell lung carcinoma" ], "AMIVANTAMAB": [ "non-small cell lung carcinoma" ], "AUMOLERTINIB": [ "non-small cell lung carcinoma" ], "BRIGATINIB": [ "non-small cell lung carcinoma", "anaplastic large cell lymphoma" ], "CETUXIMAB": [ "malignant tumor of neck", "squamous cell carcinoma", "colorectal adenocarcinoma", "colorectal carcinoma", "colorectal cancer", "head and neck neoplasm", "colorectal neoplasm" ], "CETUXIMAB SAROTALOCAN": [ "head and neck cancer" ], "DACOMITINIB": [ "non-small cell lung carcinoma" ], "ERLOTINIB": [ "non-small cell lung carcinoma", "pancreatic neoplasm" ], "GEFITINIB": [ "non-small cell lung carcinoma", "head and neck squamous cell carcinoma" ], "ICOTINIB": [], "LAPATINIB": [ "breast cancer" ], "LAPATINIB DITOSYLATE": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "LAZERTINIB": [ "non-small cell lung carcinoma" ], "MOBOCERTINIB": [ "non-small cell lung carcinoma" ], "NECITUMUMAB": [ "non-small cell lung carcinoma", "colorectal cancer", "non-small cell squamous lung carcinoma" ], "NERATINIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "NIMOTUZUMAB": [ "head and neck cancer" ], "OLMUTINIB": [], "OSIMERTINIB": [ "non-small cell lung carcinoma" ], "PANITUMUMAB": [ "colorectal cancer", "colorectal adenocarcinoma", "colorectal neoplasm" ], "ROCILETINIB": [], "VANDETANIB": [ "thyroid gland carcinoma", "medullary thyroid gland carcinoma", "thyroid tumor" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "KMT2D", "ensembl": "ENSG00000167548", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] }, { "symbol": "FBXW7", "ensembl": "ENSG00000109670", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" } ] }, { "symbol": "PTEN", "ensembl": "ENSG00000171862", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "SOX2", "ensembl": "ENSG00000181449", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" } ] }, { "symbol": "TERT", "ensembl": "ENSG00000164362", "n_drug_entries": 2, "n_distinct_drugs": 1, "drugs": { "IMETELSTAT": "APPROVAL" }, "approved": [ "IMETELSTAT" ], "n_approved": 1, "approved_for": { "IMETELSTAT": [ "anemia", "myelodysplastic syndrome" ] }, "tractability": [ { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "MYC", "ensembl": "ENSG00000136997", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] } ], "trials": { "by_antigen": { "PD-1": { "n": 46, "n_observational": 2, "n_active": 26, "n_withdrawn": 2, "trials": [ { "nct": "NCT04429542", "title": "Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-08-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04894370", "title": "Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma", "status": "RECRUITING", "last_update": "2023-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05941507", "title": "A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06270706", "title": "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06493019", "title": "Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06638931", "title": "Agnostic Therapy in Rare Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06640283", "title": "Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes", "status": "RECRUITING", "last_update": "2025-12-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06669572", "title": "Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07020247", "title": "Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study", "status": "RECRUITING", "last_update": "2025-06-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07425054", "title": "ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07555678", "title": "Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer\uff1aChase", "status": "RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07692152", "title": "Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-07-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02314169", "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02379520", "title": "HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA", "status": "COMPLETED", "last_update": "2026-04-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02408861", "title": "Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery", "status": "TERMINATED", "last_update": "2026-01-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02628067", "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02919969", "title": "Pembrolizumab in Metastatic Anal Cancer", "status": "COMPLETED", "last_update": "2023-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03233711", "title": "Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03427411", "title": "M7824 in Subjects With HPV Associated Malignancies", "status": "COMPLETED", "last_update": "2023-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03849469", "title": "A Study of XmAb\u00ae22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03894618", "title": "SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas", "status": "COMPLETED", "last_update": "2025-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04046133", "title": "Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04084951", "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2023-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04234113", "title": "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2026-03-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04272034", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-10-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04357873", "title": "Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations", "status": "COMPLETED", "last_update": "2025-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04444921", "title": "EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04472429", "title": "Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).", "status": "COMPLETED", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04536922", "title": "Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab", "status": "WITHDRAWN", "last_update": "2021-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04580485", "title": "INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-07-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04708470", "title": "A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04719988", "title": "Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04802876", "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04892043", "title": "Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2024-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04929028", "title": "Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04989387", "title": "Study of INCA 0186 in Subjects With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05060471", "title": "PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients", "status": "COMPLETED", "last_update": "2024-12-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05357898", "title": "Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2024-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05374252", "title": "Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients", "status": "UNKNOWN", "last_update": "2022-05-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05544929", "title": "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05582031", "title": "Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers", "status": "WITHDRAWN", "last_update": "2023-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05858736", "title": "Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07132463", "title": "Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07680088", "title": "Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT02379520", "title": "HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA", "status": "COMPLETED", "last_update": "2026-04-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04536922", "title": "Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab", "status": "WITHDRAWN", "last_update": "2021-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "PD-1", "retifanlimab", "Zynyz", "nivolumab", "pembrolizumab", "cemiplimab" ] }, "PD-L1": { "n": 15, "n_observational": 0, "n_active": 6, "n_withdrawn": 0, "trials": [ { "nct": "NCT05661188", "title": "Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)", "status": "RECRUITING", "last_update": "2023-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02628067", "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03074513", "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03212469", "title": "A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer", "status": "COMPLETED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03260023", "title": "Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03357757", "title": "Avelumab With Valproic Acid in Virus-associated Cancer", "status": "COMPLETED", "last_update": "2025-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03439085", "title": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers", "status": "TERMINATED", "last_update": "2024-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03519295", "title": "A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma", "status": "COMPLETED", "last_update": "2025-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03944252", "title": "Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)", "status": "UNKNOWN", "last_update": "2019-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03946358", "title": "Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)", "status": "COMPLETED", "last_update": "2024-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04084951", "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2023-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04230759", "title": "Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04432597", "title": "HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers", "status": "COMPLETED", "last_update": "2026-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07280377", "title": "A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "PD-L1", "atezolizumab", "durvalumab", "avelumab" ] }, "EGFR": { "n": 9, "n_observational": 1, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04429542", "title": "Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-08-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00316888", "title": "Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer", "status": "COMPLETED", "last_update": "2023-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00324415", "title": "Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer", "status": "COMPLETED", "last_update": "2025-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00397384", "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer", "status": "COMPLETED", "last_update": "2015-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00955240", "title": "Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer", "status": "TERMINATED", "last_update": "2020-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01285778", "title": "Vectibix for the Treatment of Anal Cancer", "status": "COMPLETED", "last_update": "2018-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01581840", "title": "Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus", "status": "COMPLETED", "last_update": "2024-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01621217", "title": "Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0", "status": "COMPLETED", "last_update": "2020-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03944252", "title": "Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)", "status": "UNKNOWN", "last_update": "2019-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "EGFR", "cetuximab", "panitumumab" ] }, "HPV E6/E7": { "n": 42, "n_observational": 5, "n_active": 10, "n_withdrawn": 1, "trials": [ { "nct": "NCT05266898", "title": "Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV", "status": "RECRUITING", "last_update": "2025-04-18", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05334706", "title": "A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)", "status": "RECRUITING", "last_update": "2026-02-23", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05639972", "title": "E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05686226", "title": "E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00019110", "title": "Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer", "status": "COMPLETED", "last_update": "2015-04-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00666107", "title": "Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men", "status": "UNKNOWN", "last_update": "2012-03-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01209325", "title": "Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males", "status": "COMPLETED", "last_update": "2020-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01651949", "title": "Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)", "status": "COMPLETED", "last_update": "2018-11-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01923116", "title": "Therapeutic HPV-16 Vaccination for the Treatment of Anal Dysplasia", "status": "COMPLETED", "last_update": "2018-03-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01946139", "title": "Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV", "status": "COMPLETED", "last_update": "2023-11-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02087384", "title": "HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN)", "status": "COMPLETED", "last_update": "2021-03-05", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02280811", "title": "T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers", "status": "COMPLETED", "last_update": "2017-09-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02379520", "title": "HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA", "status": "COMPLETED", "last_update": "2026-04-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02503111", "title": "The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men", "status": "TERMINATED", "last_update": "2022-06-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02858310", "title": "E7 TCR T Cells for Human Papillomavirus-Associated Cancers", "status": "COMPLETED", "last_update": "2026-03-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02865135", "title": "Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer", "status": "COMPLETED", "last_update": "2024-01-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03051516", "title": "HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions", "status": "TERMINATED", "last_update": "2024-02-28", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03346915", "title": "Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention", "status": "COMPLETED", "last_update": "2019-10-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03439085", "title": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers", "status": "TERMINATED", "last_update": "2024-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03489707", "title": "The Prevent Anal Cancer Self-Swab Study", "status": "COMPLETED", "last_update": "2024-11-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03499795", "title": "VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2", "status": "COMPLETED", "last_update": "2023-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03603808", "title": "VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions", "status": "COMPLETED", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03946358", "title": "Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)", "status": "COMPLETED", "last_update": "2024-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03947775", "title": "HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL", "status": "UNKNOWN", "last_update": "2022-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04084951", "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2023-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04287868", "title": "Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies", "status": "COMPLETED", "last_update": "2026-06-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04432597", "title": "HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers", "status": "COMPLETED", "last_update": "2026-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04635423", "title": "Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064)", "status": "COMPLETED", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04905030", "title": "Education, Immigration and HPV Vaccination: an Informational Randomized Trial", "status": "UNKNOWN", "last_update": "2021-06-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05357898", "title": "Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2024-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05518201", "title": "Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old", "status": "COMPLETED", "last_update": "2024-04-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05662020", "title": "A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2022-12-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05668572", "title": "A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine", "status": "UNKNOWN", "last_update": "2023-01-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05680454", "title": "A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine", "status": "COMPLETED", "last_update": "2023-01-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05694728", "title": "A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine", "status": "COMPLETED", "last_update": "2023-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05959564", "title": "A Chatbot Intervention for Reducing HPV Vaccine Hesitancy", "status": "COMPLETED", "last_update": "2024-10-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05973487", "title": "A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06358053", "title": "CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2024-04-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06465914", "title": "A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06528353", "title": "Blood Biomarkers Based Screening for HPV-driven OPC", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06866574", "title": "A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07090174", "title": "CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV", "status": "WITHDRAWN", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 6, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT05639972", "title": "E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05686226", "title": "E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02379520", "title": "HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA", "status": "COMPLETED", "last_update": "2026-04-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02858310", "title": "E7 TCR T Cells for Human Papillomavirus-Associated Cancers", "status": "COMPLETED", "last_update": "2026-03-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05973487", "title": "A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06358053", "title": "CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2024-04-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "HPV E6", "HPV E7", "E6/E7", "HPV16 E7", "ISA101", "VGX-3100", "human papillomavirus vaccine" ] }, "CTLA-4": { "n": 9, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT02314169", "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02408861", "title": "Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery", "status": "TERMINATED", "last_update": "2026-01-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03212469", "title": "A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer", "status": "COMPLETED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03849469", "title": "A Study of XmAb\u00ae22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04084951", "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2023-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04892043", "title": "Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2024-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05858736", "title": "Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "CTLA-4", "ipilimumab" ] }, "TROP2": { "n": 2, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT05941507", "title": "A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07511023", "title": "Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "TROP2", "TACSTD2", "sacituzumab" ] } }, "by_drug": { "ATEZOLIZUMAB": { "n": 9, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT05661188", "title": "Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)", "status": "RECRUITING", "last_update": "2023-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03074513", "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03212469", "title": "A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer", "status": "COMPLETED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03519295", "title": "A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma", "status": "COMPLETED", "last_update": "2025-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03946358", "title": "Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)", "status": "COMPLETED", "last_update": "2024-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04084951", "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2023-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04432597", "title": "HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers", "status": "COMPLETED", "last_update": "2026-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07280377", "title": "A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AVELUMAB": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT03260023", "title": "Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03357757", "title": "Avelumab With Valproic Acid in Virus-associated Cancer", "status": "COMPLETED", "last_update": "2025-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03944252", "title": "Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)", "status": "UNKNOWN", "last_update": "2019-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "BINTRAFUSP ALFA": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04708470", "title": "A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CAMRELIZUMAB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06304545", "title": "Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CEMIPLIMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "CETUXIMAB": { "n": 6, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00316888", "title": "Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer", "status": "COMPLETED", "last_update": "2023-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00324415", "title": "Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer", "status": "COMPLETED", "last_update": "2025-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00397384", "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer", "status": "COMPLETED", "last_update": "2015-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00955240", "title": "Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer", "status": "TERMINATED", "last_update": "2020-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01621217", "title": "Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0", "status": "COMPLETED", "last_update": "2020-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03944252", "title": "Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)", "status": "UNKNOWN", "last_update": "2019-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DURVALUMAB": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT03212469", "title": "A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer", "status": "COMPLETED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03439085", "title": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers", "status": "TERMINATED", "last_update": "2024-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04230759", "title": "Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ERLOTINIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00030498", "title": "Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction", "status": "COMPLETED", "last_update": "2013-01-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00397384", "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer", "status": "COMPLETED", "last_update": "2015-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "NIMOTUZUMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01382745", "title": "Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers", "status": "TERMINATED", "last_update": "2013-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NIVOLUMAB": { "n": 11, "n_observational": 1, "n_active": 6, "n_withdrawn": 0, "trials": [ { "nct": "NCT06638931", "title": "Agnostic Therapy in Rare Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02314169", "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02379520", "title": "HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA", "status": "COMPLETED", "last_update": "2026-04-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02408861", "title": "Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery", "status": "TERMINATED", "last_update": "2026-01-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03233711", "title": "Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04084951", "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2023-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04444921", "title": "EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04892043", "title": "Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2024-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04929028", "title": "Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PANITUMUMAB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01285778", "title": "Vectibix for the Treatment of Anal Cancer", "status": "COMPLETED", "last_update": "2018-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01581840", "title": "Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus", "status": "COMPLETED", "last_update": "2024-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PEMBROLIZUMAB": { "n": 16, "n_observational": 0, "n_active": 9, "n_withdrawn": 1, "trials": [ { "nct": "NCT04429542", "title": "Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-08-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06270706", "title": "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06493019", "title": "Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06640283", "title": "Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes", "status": "RECRUITING", "last_update": "2025-12-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06669572", "title": "Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02628067", "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02919969", "title": "Pembrolizumab in Metastatic Anal Cancer", "status": "COMPLETED", "last_update": "2023-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03849469", "title": "A Study of XmAb\u00ae22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04046133", "title": "Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04234113", "title": "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2026-03-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04357873", "title": "Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations", "status": "COMPLETED", "last_update": "2025-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04536922", "title": "Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab", "status": "WITHDRAWN", "last_update": "2021-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05357898", "title": "Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2024-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05544929", "title": "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07680088", "title": "Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "RETIFANLIMAB": { "n": 3, "n_observational": 1, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT07425054", "title": "ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04472429", "title": "Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).", "status": "COMPLETED", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04989387", "title": "Study of INCA 0186 in Subjects With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "SERPLULIMAB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT07020247", "title": "Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study", "status": "RECRUITING", "last_update": "2025-06-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "SINTILIMAB": { "n": 3, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT07555678", "title": "Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer\uff1aChase", "status": "RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07692152", "title": "Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2026-07-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05374252", "title": "Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients", "status": "UNKNOWN", "last_update": "2022-05-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "SPARTALIZUMAB": { "n": 3, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT04894370", "title": "Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma", "status": "RECRUITING", "last_update": "2023-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05941507", "title": "A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04802876", "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TISLELIZUMAB": { "n": 3, "n_observational": 0, "n_active": 2, "n_withdrawn": 1, "trials": [ { "nct": "NCT04802876", "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05582031", "title": "Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers", "status": "WITHDRAWN", "last_update": "2023-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07132463", "title": "Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "TORIPALIMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT05060471", "title": "PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients", "status": "COMPLETED", "last_update": "2024-12-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VANDETANIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00532909", "title": "Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer", "status": "COMPLETED", "last_update": "2012-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] } } } }